BACKGROUND/AIMS: Currently known mutations account for less than 15% of cases with normosmic hypogonadotropic hypogonadism (nIHH). The objective of the study was to identify novel hereditary associations in the pathogenesis of nIHH. METHODS: We investigated 26 Turkish patients with nIHH (21 males and 5 females) from 22 families. The coding regions of the GnRH receptor, GnRH1, GPR54, and KISS1 genes were directly sequenced. RESULTS: In two sisters, a novel homozygous missense mutation, R139C, located in the conserved DRS motif at the junction of the third transmembrane and the second intracellular loop of the GnRH receptor was identified. The R139C mutation almost completely abolished plasma membrane expression while having little effect on GnRH-binding affinity. The mutant receptor expression was rescued by a membrane-permeant, non-peptide GnRH receptor antagonist IN3. CONCLUSIONS: Consistent with the previous studies we were able to find mutations in only 7.6% of a well-defined group of patients with nIHH, which further suggests that yet unidentified genetic associations to explain nIHH exist.
BACKGROUND/AIMS: Currently known mutations account for less than 15% of cases with normosmic hypogonadotropic hypogonadism (nIHH). The objective of the study was to identify novel hereditary associations in the pathogenesis of nIHH. METHODS: We investigated 26 Turkish patients with nIHH (21 males and 5 females) from 22 families. The coding regions of the GnRH receptor, GnRH1, GPR54, and KISS1 genes were directly sequenced. RESULTS: In two sisters, a novel homozygous missense mutation, R139C, located in the conserved DRS motif at the junction of the third transmembrane and the second intracellular loop of the GnRH receptor was identified. The R139C mutation almost completely abolished plasma membrane expression while having little effect on GnRH-binding affinity. The mutant receptor expression was rescued by a membrane-permeant, non-peptide GnRH receptor antagonist IN3. CONCLUSIONS: Consistent with the previous studies we were able to find mutations in only 7.6% of a well-defined group of patients with nIHH, which further suggests that yet unidentified genetic associations to explain nIHH exist.
Authors: Magdalena Avbelj Stefanija; Marc Jeanpierre; Gerasimos P Sykiotis; Jacques Young; Richard Quinton; Ana Paula Abreu; Lacey Plummer; Margaret G Au; Ravikumar Balasubramanian; Andrew A Dwyer; Jose C Florez; Timothy Cheetham; Simon H Pearce; Radhika Purushothaman; Albert Schinzel; Michel Pugeat; Elka E Jacobson-Dickman; Svetlana Ten; Ana Claudia Latronico; James F Gusella; Catherine Dode; William F Crowley; Nelly Pitteloud Journal: Hum Mol Genet Date: 2012-07-05 Impact factor: 6.150
Authors: Hyung-Goo Kim; Jennifer Pedersen-White; Balasubramanian Bhagavath; Lawrence C Layman Journal: Front Horm Res Date: 2010-04-08 Impact factor: 2.606
Authors: Daiane Beneduzzi; Ericka B Trarbach; Le Min; Alexander A L Jorge; Heraldo M Garmes; Alessandra Covallero Renk; Marta Fichna; Piotr Fichna; Karina A Arantes; Elaine M F Costa; Anna Zhang; Oluwaseun Adeola; Junping Wen; Rona S Carroll; Berenice B Mendonça; Ursula B Kaiser; Ana Claudia Latronico; Letícia F G Silveira Journal: Fertil Steril Date: 2014-07-10 Impact factor: 7.329
Authors: Fatih Gürbüz; L Damla Kotan; Eda Mengen; Zeynep Şıklar; Merih Berberoğlu; Sebila Dökmetaş; Mehmet Fatih Kılıçlı; Ayla Güven; Birgül Kirel; Nurçin Saka; Şükran Poyrazoğlu; Yaşar Cesur; Murat Doğan; Samim Özen; Mehmet Nuri Özbek; Hüseyin Demirbilek; M Burcu Kekil; Fatih Temiz; Neslihan Önenli Mungan; Bilgin Yüksel; Ali Kemal Topaloğlu Journal: J Clin Res Pediatr Endocrinol Date: 2012-07-05
Authors: Javier A Tello; Claire L Newton; Jerome Bouligand; Anne Guiochon-Mantel; Robert P Millar; Jacques Young Journal: PLoS One Date: 2012-06-05 Impact factor: 3.240